Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Specialty hubs

Have your say on Medicine Matters

Visit the conference hub

Editor's pick

08-07-2020 | Non-small-cell lung cancer | Highlight | News

Pyrotinib activity shown in HER2-mutant NSCLC

The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.

01-07-2020 | COVID-19 | Highlight | News

COVID-19: Oncology clinical trials enrollment falls

The COVID-19 outbreak is associated with a decrease in accrual to cancer clinical trials, indicate US data.

27-05-2020 | COVID-19 | Podcast | Article

Conducting cancer clinical trials in the COVID-19 era

Gary Lyman discusses the effects of the coronavirus pandemic on various aspects of oncology clinical trials, from accrual to analysis, and highlights the need for robust research on COVID-19 and cancer.

Latest from across the site

10-07-2020 | COVID-19 | News

Cancer associated with COVID-19 mortality risk in large UK study

A large UK study using the OpenSAFELY analytics platform has found that people with cancer, particularly those with hematologic malignancies, may have an elevated risk for COVID-19-related death.

10-07-2020 | COVID-19 | News

New York City data suggest link between immunotherapy, poor COVID-19 outcomes

Treatment with immune checkpoint inhibitors may increase the risk for poor outcomes among patients with cancer and comorbid SARS-CoV-2 infection, indicate data from New York City in the USA.

08-07-2020 | Breast cancer | News

TRAXHER2: No support for capecitabine addition in HER2-positive breast cancer

The addition of capecitabine to trastuzumab emtansine does not improve the clinical outcomes of patients with previously treated HER2-positive metastatic breast cancer, indicates the phase 1/2 TRAXHER2 study.

08-07-2020 | Non-small-cell lung cancer | Highlight | News

Pyrotinib activity shown in HER2-mutant NSCLC

The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.

07-07-2020 | COVID-19 | News

Guidelines for managing immune-related pneumonitis during COVID-19 published

More information about these consensus recommendations available here

Meet the Editorial Board


Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

Image Credits